KRAS and gastric cancer: The ability of both anti-Kras and nonsense nanobeacons to silence Kras was evaluated in gastric cancer cells, where only the anti-Kras nanobeacons provided a robust knockdown in a dose dependent manner, with a median effective dose (ED50) between 1 and 5 nM.